{"id":"meticillin","rwe":[{"pmid":"41821921","year":"2026","title":"A Retrospective, Descriptive Analysis of MRSA Infections in a Low-Endemicity Region, Focusing on Empiric Treatment Adequacy.","finding":"","journal":"Infection and drug resistance","studyType":"Clinical Study"},{"pmid":"41798992","year":"2026","title":"Mobile phone contamination among hospital staff: Focus on MRSA and ESBL-producing bacteria.","finding":"","journal":"Journal of infection prevention","studyType":"Clinical Study"},{"pmid":"41757426","year":"2026","title":"Evaluation of the Antimicrobial Activity of a 3% Chlorhexidine/Ophytrium Mousse and Shampoo in 18 Healthy Dogs.","finding":"","journal":"Veterinary dermatology","studyType":"Clinical Study"},{"pmid":"41653018","year":"2026","title":"Surgical methods for reducing early wound dehiscence after reconstruction surgery for pressure ulcer.","finding":"","journal":"Journal of wound care","studyType":"Clinical Study"},{"pmid":"41626231","year":"2026","title":"Case Report: Fulminant shock due to PVL-positive Staphylococcus aureus in an adolescent-superantigen-negative sepsis with toxic shock-like features.","finding":"","journal":"Frontiers in medicine","studyType":"Clinical Study"}],"tags":[{"label":"meticillin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01CF03","category":"atc"},{"label":"Active","category":"status"},{"label":"Bacterial septicemia","category":"indication"},{"label":"Infection of skin AND/OR subcutaneous tissue","category":"indication"},{"label":"Sinusitis","category":"indication"},{"label":"Staphylococcal pneumonia","category":"indication"},{"label":"Apothecon","category":"company"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Infectious mononucleosis","Kidney disease","Pseudomembranous enterocolitis"]},"trials":[],"aliases":[],"company":"Bristol-Myers Squibb","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=meticillin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:12:16.879145+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:12:36.126949+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:12:23.867198+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=meticillin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:12:24.197221+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL575/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:24.898197+00:00"}},"allNames":"metacillin","offLabel":[],"synonyms":["meticillin sodium","staphcillin","meticillin","metacillin","methicillin","methycillin","methicillin sodium"],"timeline":[],"aiSummary":"Meticillin, marketed by Bristol-Myers Squibb, is an established antibiotic primarily indicated for treating bacterial septicemia, with a key composition patent expiring in 2028. Its mechanism of action, which inhibits bacterial cell wall synthesis, provides a strong therapeutic foundation against gram-positive bacteria. However, the presence of multiple off-patent competitors in the same class, including dicloxacillin, cloxacillin, oxacillin, and nafcillin, poses a significant threat to its market share.","approvals":[{"date":"","orphan":false,"company":"APOTHECON","regulator":"FDA"}],"brandName":"Metacillin","ecosystem":[{"indication":"Bacterial septicemia","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"}],"globalPrevalence":null},{"indication":"Infection of skin AND/OR subcutaneous tissue","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"}],"globalPrevalence":null},{"indication":"Sinusitis","otherDrugs":[{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"bacampicillin","slug":"bacampicillin","company":""},{"name":"cloxacillin","slug":"cloxacillin","company":"Glaxosmithkline"}],"globalPrevalence":null},{"indication":"Staphylococcal pneumonia","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"cefapirin","slug":"cefapirin","company":"Apothecon"}],"globalPrevalence":null}],"mechanism":{"novelty":"First-in-class","modality":"Small Molecule","drugClass":"meticillin","explanation":"","oneSentence":"","technicalDetail":"Metacillin exerts its antibacterial effect by binding to and inhibiting the transpeptidase enzyme, which is essential for bacterial cell wall synthesis, thereby preventing the formation of a stable cell wall and ultimately leading to cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1744","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=meticillin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=meticillin","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:41:19.136290","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:12:36.127012+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dicloxacillin","drugSlug":"dicloxacillin","fdaApproval":"1968-04-22","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cloxacillin","drugSlug":"cloxacillin","fdaApproval":"1974-09-17","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"oxacillin","drugSlug":"oxacillin","fdaApproval":"1971-04-08","genericCount":15,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nafcillin","drugSlug":"nafcillin","fdaApproval":"1965-10-11","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"meticillin","indications":{"approved":[{"name":"Bacterial septicemia","source":"DrugCentral","snomedId":10001005,"regulator":"FDA"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA"},{"name":"Sinusitis","source":"DrugCentral","snomedId":36971009,"regulator":"FDA"},{"name":"Staphylococcal pneumonia","source":"DrugCentral","snomedId":22754005,"regulator":"FDA"}],"offLabel":[{"name":"Bacterial endocarditis","source":"DrugCentral","drugName":"meticillin"},{"name":"Cholangitis","source":"DrugCentral","drugName":"meticillin","evidenceCount":16,"evidenceLevel":"moderate"},{"name":"Staphylococcal meningitis","source":"DrugCentral","drugName":"meticillin","evidenceCount":439,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dicloxacillin","brandName":"dicloxacillin","genericName":"dicloxacillin","approvalYear":"1968","relationship":"same-class"},{"drugId":"cloxacillin","brandName":"cloxacillin","genericName":"cloxacillin","approvalYear":"1974","relationship":"same-class"},{"drugId":"oxacillin","brandName":"oxacillin","genericName":"oxacillin","approvalYear":"1971","relationship":"same-class"},{"drugId":"nafcillin","brandName":"nafcillin","genericName":"nafcillin","approvalYear":"1965","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02694458","phase":"NA","title":"Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-02-23","conditions":["Methicillin-resistant Staphylococcal Infections"],"enrollment":100,"completionDate":"2017-02-15"},{"nctId":"NCT06958835","phase":"NA","title":"Linezolid Plus Standard of Care","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-10-06","conditions":["Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)"],"enrollment":606,"completionDate":"2028-10"},{"nctId":"NCT06637332","phase":"PHASE4","title":"Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia","status":"RECRUITING","sponsor":"Todd C. Lee MD MPH FIDSA","startDate":"2024-11-14","conditions":["Staphylococcus Aureus Septicemia","Staphylococcus Aureus Bacteremia","S. Aureus Bacteremia","S. Aureus Bloodstream Infection","Staphylococcus Aureus Endocarditis"],"enrollment":300,"completionDate":"2027-11"},{"nctId":"NCT02572791","phase":"PHASE4","title":"Staph Household Intervention for Eradication (SHINE)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-10","conditions":["Skin and Subcutaneous Tissue Bacterial Infections","Staphylococcus Aureus","MRSA - Methicillin Resistant Staphylococcus Aureus Infection"],"enrollment":835,"completionDate":"2024-12"},{"nctId":"NCT03683329","phase":"PHASE3","title":"Antibiotic De-escalation in Onco-hematology Patients for Sepsis or Septic Shock","status":"COMPLETED","sponsor":"Institut Paoli-Calmettes","startDate":"2018-11-26","conditions":["Critical Care","Cancer"],"enrollment":398,"completionDate":"2024-07-26"},{"nctId":"NCT03489629","phase":"PHASE2","title":"STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2018-04-03","conditions":["Cystic Fibrosis"],"enrollment":37,"completionDate":"2026-01-31"},{"nctId":"NCT04886284","phase":"PHASE2","title":"Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia","status":"RECRUITING","sponsor":"Todd C. Lee MD MPH FIDSA","startDate":"2024-05-20","conditions":["Staphylococcus Aureus Bacteremia","Staphylococcus Aureus Septicemia","Staphylococcal Sepsis","Staphylococcus Aureus Endocarditis"],"enrollment":60,"completionDate":"2026-07"},{"nctId":"NCT06954129","phase":"PHASE4","title":"A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-01-28","conditions":["Acute Kidney Injury"],"enrollment":750,"completionDate":"2029-07"},{"nctId":"NCT07378982","phase":"NA","title":"3D Printed Ceramic-Filled Photopolymer Resin Vs. CAD/CAM Resin Composite Overlays for Restoration of Extensively Damaged Endodontically Treated Posterior Teeth. An 18-month Follow-up","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-02-01","conditions":["Endodontically Treated Molar","Dental Restoration, Permanent"],"enrollment":32,"completionDate":"2027-10-01"},{"nctId":"NCT07382271","phase":"NA","title":"Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-02","conditions":["Urinary Tract Infections","Urinary Tract Infections Caused by Drug-resistant Bacteria"],"enrollment":6,"completionDate":"2026-08"},{"nctId":"NCT07376889","phase":"PHASE4","title":"Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia","status":"NOT_YET_RECRUITING","sponsor":"Intermountain Health Care, Inc.","startDate":"2026-02-01","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":2096,"completionDate":"2029-01"},{"nctId":"NCT06210594","phase":"PHASE4","title":"Staph Intervention for Effective Local Defense","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2024-04-01","conditions":["Staphylococcus Aureus Infection"],"enrollment":78,"completionDate":"2025-11-14"},{"nctId":"NCT05079620","phase":"PHASE4","title":"Early Antibiotics After Aspiration in ICU Patients","status":"TERMINATED","sponsor":"UConn Health","startDate":"2021-11-30","conditions":["Aspiration","Aspiration Pneumonia"],"enrollment":5,"completionDate":"2024-04-12"},{"nctId":"NCT03012360","phase":"PHASE4","title":"Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2018-02-08","conditions":["Mechanical Ventilation Complication","Critical Illness"],"enrollment":103,"completionDate":"2024-07-07"},{"nctId":"NCT03248063","phase":"NA","title":"Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-09-05","conditions":["Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus"],"enrollment":315,"completionDate":"2025-03-10"},{"nctId":"NCT01209234","phase":"NA","title":"Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2011-01","conditions":["Methicillin-resistant Staphylococcus Aureus"],"enrollment":2140,"completionDate":"2019-01"},{"nctId":"NCT05632315","phase":"PHASE2","title":"PMT for MDRO Decolonization","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-08-19","conditions":["Multidrug Resistant Bacterial Infection","Enterobacteriaceae Infections","Pseudomonas Aeruginosa","VRE Infection","Methicillin-resistant Staphylococcus Aureus"],"enrollment":150,"completionDate":"2026-05"},{"nctId":"NCT05137119","phase":"PHASE4","title":"Staphylococcus Aureus Network Adaptive Platform Trial","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2022-02-16","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":8000,"completionDate":"2028-12-01"},{"nctId":"NCT07186894","phase":"","title":"Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2000-01-01","conditions":["Bacteriemia","Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection"],"enrollment":5000,"completionDate":"2026-09-01"},{"nctId":"NCT05975671","phase":"NA","title":"Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-08-21","conditions":["Sepsis","Sepsis Mrsa","Sepsis Bacteremia","Antimicrobial - Induced Nephropathy","Sepsis, Severe","Septic Shock","Septic Syndrome"],"enrollment":52500,"completionDate":"2026-05"},{"nctId":"NCT04715087","phase":"NA","title":"Staphylococcus Aureus in Atopic Dermatitis Immunopathology","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2022-10-26","conditions":["Atopic Dermatitis"],"enrollment":7,"completionDate":"2025-01-31"},{"nctId":"NCT05939479","phase":"","title":"Antistaphylococcal Betalactam and Emergence of Resistance","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2018-01-01","conditions":["Bacterial Resistance","Methicillin-Sensitive Staphylococcus Aureus Infection"],"enrollment":644,"completionDate":"2023-06-01"},{"nctId":"NCT06758362","phase":"NA","title":"EMDR vs. CBT for PTSD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Nisantasi University","startDate":"2024-12-01","conditions":["Post Traumatic Stress Disorder PTSD"],"enrollment":89,"completionDate":"2025-07-15"},{"nctId":"NCT06456424","phase":"PHASE1,PHASE2","title":"Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Calgary","startDate":"2024-11-20","conditions":["Prosthetic Joint Infections of Hip","Staphylococcus Aureus Infection"],"enrollment":1,"completionDate":"2025-11"},{"nctId":"NCT06982105","phase":"PHASE4","title":"Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections","status":"RECRUITING","sponsor":"Indiana University","startDate":"2025-05-20","conditions":["Methicillin Resistant Staphylococcus Aureus","Osteomyelitis Acute","Septic Arthritis","Orbital Cellulitis","Facial Cellulitis","Mastoiditis","Cervical Adenitis","Retropharyngeal Abscess","Peritonsillar Abscess"],"enrollment":100,"completionDate":"2027-06"},{"nctId":"NCT06959667","phase":"","title":"Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-15","conditions":["Methicillin-susceptible S. Aureus (MSSA)","Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA)","Complicated Skin and Soft Tissue,cSSTI"],"enrollment":144,"completionDate":"2025-12-31"},{"nctId":"NCT05422144","phase":"NA","title":"Cleanser for Acute Wounds","status":"WITHDRAWN","sponsor":"Rochal Industries LLC","startDate":"2024-01-01","conditions":["Acute Wound"],"enrollment":0,"completionDate":"2025-04-30"},{"nctId":"NCT00532324","phase":"NA","title":"A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2008-02","conditions":["Staphylococcus Aureus"],"enrollment":107,"completionDate":"2013-10"},{"nctId":"NCT06872099","phase":"","title":"NAsal MEthicillin-resistant Staphylococcus (NAMES): a Prospective Study to Assess the Impact of Antibiotic Therapy on Nasal Colonization with Methicillin-resistant Staphylococcus Aureus (MRSA) Inhospitalized Children","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2021-11-06","conditions":["NAsal MEthicillin-resistant Staphylococcus"],"enrollment":76,"completionDate":"2025-03-19"},{"nctId":"NCT00560599","phase":"PHASE3","title":"A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection","status":"COMPLETED","sponsor":"loren g miller","startDate":"2007-04","conditions":["Methicillin Resistant Staphylococcus Aureus Skin Infections"],"enrollment":350,"completionDate":"2012-12"},{"nctId":"NCT00247871","phase":"","title":"Microbiological Characterization and Nasal Carriage Rates of Methicillin Resistant Staphylococcus Aureus (MRSA) in Vancouver Downtown Eastside","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2005-10-01","conditions":["Nasal Colonization With MRSA Bacteria"],"enrollment":600,"completionDate":"2012-12-01"},{"nctId":"NCT00247858","phase":"","title":"Analysis of Methicillin Resistant Staphylococcus Aureus (MRSA) Obtained Through the Emergency Department in a Tertiary Care Hospital in Vancouver Canada From 2001-2005","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2005-01-01","conditions":["Infection With MRSA Bacteria"],"enrollment":97,"completionDate":"2012-12-01"},{"nctId":"NCT06814223","phase":"PHASE4","title":"Using Antibiotics to Prevent Infections in Hemodialysis Patients During Catheter Placement","status":"RECRUITING","sponsor":"Western Galilee Hospital-Nahariya","startDate":"2024-10-28","conditions":["Infection Catheter-Related"],"enrollment":200,"completionDate":"2028-06-30"},{"nctId":"NCT03583333","phase":"PHASE3","title":"Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-18","conditions":["Hospital-Acquired Bacterial Pneumonia","Ventilator-Associated Bacterial Pneumonia"],"enrollment":274,"completionDate":"2022-07-12"},{"nctId":"NCT06044272","phase":"","title":"Antimicrobial Resistance in Hospitals From Meta, Colombia","status":"COMPLETED","sponsor":"Hospital Departamental de Villavicencio","startDate":"2023-09-01","conditions":["Increased Drug Resistance"],"enrollment":10000,"completionDate":"2024-06-30"},{"nctId":"NCT04775953","phase":"PHASE2","title":"DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":["Staphylococcal Bacteraemia"],"enrollment":200,"completionDate":"2023-12-01"},{"nctId":"NCT05529173","phase":"PHASE4","title":"Povidone-Iodine for Nasal Decolonization","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-09-06","conditions":["Surgical Wound Infection","Preoperative Care","Methicillin-Resistant Staphylococcus Aureus"],"enrollment":192,"completionDate":"2023-11-17"},{"nctId":"NCT05887856","phase":"NA","title":"Reduction of Pre-operative Anxiety Using a Specially Designed Educational Program for Breast Cancer Patients Undergoing Surgery: a Randomized Controlled Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2024-11-01","conditions":["Patient Satisfaction","Preoperative Anxiety","Anxiety"],"enrollment":400,"completionDate":"2025-10"},{"nctId":"NCT06634940","phase":"","title":"International Surveillance of Antimicrobial Resistance in Cirrhosis-Related Infections","status":"RECRUITING","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2020-11-15","conditions":["Cirrhosis","Bacterial Infections","Multidrug Resistance"],"enrollment":1000,"completionDate":"2031-06-01"},{"nctId":"NCT02814916","phase":"PHASE3","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-30","conditions":["Methicillin-Resistant Staphylococcus Aureus","Bacterial Infections","Staphylococcal Skin Infections"],"enrollment":199,"completionDate":"2024-01-01"},{"nctId":"NCT02363166","phase":"","title":"Analysis of CA-MRSA Transmission: An ED Population Sampling Strategy","status":"COMPLETED","sponsor":"University of Florida","startDate":"2015-08","conditions":["Methicillin-Resistant Staphylococcus Aureus"],"enrollment":575,"completionDate":"2018-04-04"},{"nctId":"NCT06495697","phase":"","title":"Plasma Pharmacological Monitoring of M Penicillins in Methicillin-sensitive Staphylococcus Aureus Bacteremia","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-07-19","conditions":["Staphylococcus Aureus Infection"],"enrollment":200,"completionDate":"2024-07-19"},{"nctId":"NCT00766259","phase":"","title":"Relationship of Staphylococcal Colonization to Infection","status":"WITHDRAWN","sponsor":"Veterans BioMedical Research Institute","startDate":"2009-07","conditions":["MRSA Infection"],"enrollment":0,"completionDate":"2012-06"},{"nctId":"NCT06267352","phase":"","title":"Epidemiology and Genomic Surveillance of Staphylococcus Aureus in ICU Neonatology","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Caen","startDate":"2024-03","conditions":["the Aim of This Study is to Describe Genomic Epidemiology of MSSA in Neonatal ICU"],"enrollment":120,"completionDate":"2026-06"},{"nctId":"NCT06189885","phase":"NA","title":"Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2024-08-01","conditions":["Periprosthetic Joint Infection"],"enrollment":184,"completionDate":"2026-07-31"},{"nctId":"NCT00501150","phase":"NA","title":"Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2005-09","conditions":["Gram-positive Bacterial Infections","Staphylococcal Infections"],"enrollment":211,"completionDate":"2007-06"},{"nctId":"NCT05278013","phase":"NA","title":"Utility of 2- Octyl Cyanoacrylate (2-OCA)","status":"UNKNOWN","sponsor":"Methodist Health System","startDate":"2022-01-13","conditions":["Ascites","Fluid Loss"],"enrollment":134,"completionDate":"2024-01-13"},{"nctId":"NCT05880069","phase":"","title":"Clinical Outcomes in Patients With Infection by Resistant Microorganism","status":"UNKNOWN","sponsor":"Hospital Universitario Virgen Macarena","startDate":"2022-10-01","conditions":["Pneumonia","Bloodstream Infection","Urinary Tract Infections","Skin Infection","Surgical Site Infection","Staphylococcus Aureus","Klebsiella Pneumonia","Escherichia Coli","Enterococcus Faecium Infection","Acinetobacter Infections","Pseudomonas Aeruginosa"],"enrollment":5000,"completionDate":"2023-10"},{"nctId":"NCT03439124","phase":"PHASE3","title":"Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2017-11-27","conditions":["Community-acquired Pneumonia (CAP)","Hospital-acquired Pneumonia (HAP)"],"enrollment":138,"completionDate":"2020-03-16"},{"nctId":"NCT00324922","phase":"PHASE3","title":"Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-05-01","conditions":["Osteomyelitis","Methicillin-resistant Staphylococcus Aureus"],"enrollment":2,"completionDate":"2007-05-01"},{"nctId":"NCT01011335","phase":"PHASE1,PHASE2","title":"Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2009-11","conditions":["Staphylococcus Aureus"],"enrollment":176,"completionDate":"2011-03"},{"nctId":"NCT00631566","phase":"NA","title":"Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2007-05","conditions":["HIV Infections","Staphylococcal Infections"],"enrollment":550,"completionDate":"2017-10"},{"nctId":"NCT00859677","phase":"","title":"Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2009-03","conditions":["HIV Infections","Staphylococcal Infections"],"enrollment":52,"completionDate":"2016-08-26"},{"nctId":"NCT02660554","phase":"NA","title":"Trial of MRSA Polymerase Chain Reaction for Pneumonia","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-01","conditions":["Pneumonia","Methicillin-Resistant Staphylococcus Aureus"],"enrollment":45,"completionDate":"2019-05-03"},{"nctId":"NCT01105767","phase":"NA","title":"Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2010-05","conditions":["Staphylococcus Aureus","MRSA Skin Infections","Staphylococcal Skin Infections"],"enrollment":30209,"completionDate":"2012-01"},{"nctId":"NCT04873557","phase":"NA","title":"Copper Use as Protection Against Antimicrobial Resistance in the ICU","status":"COMPLETED","sponsor":"Universidad del Desarrollo","startDate":"2020-11-02","conditions":["Healthcare Associated Infection"],"enrollment":168,"completionDate":"2022-12-31"},{"nctId":"NCT03181932","phase":"PHASE3","title":"AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"Savara Inc.","startDate":"2017-09-20","conditions":["MRSA","Cystic Fibrosis"],"enrollment":188,"completionDate":"2021-01-15"},{"nctId":"NCT01593761","phase":"PHASE2","title":"Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus","status":"COMPLETED","sponsor":"CrystalGenomics, Inc.","startDate":"2012-06","conditions":["Skin Infection"],"enrollment":20,"completionDate":"2012-10"},{"nctId":"NCT04597242","phase":"","title":"Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia","status":"NO_LONGER_AVAILABLE","sponsor":"ContraFect","startDate":"","conditions":["MRSA Bloodstream Infection","MRSA Bacteremia","MRSA Right-sided Endocarditis","Covid19"],"enrollment":0,"completionDate":""},{"nctId":"NCT04285697","phase":"NA","title":"Infection Prevention Bundle in Brain Tumor Surgery","status":"SUSPENDED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2020-02-20","conditions":["Surgical Site Infection","Brain Tumor"],"enrollment":300,"completionDate":"2022-12-03"},{"nctId":"NCT05474118","phase":"","title":"Real-life Use of Cefazolin for the Treatment of Meticillin-susceptible Staphylococcal Infective Endocarditis: Comparison to a Treatment Cohort With Penicillin M","status":"COMPLETED","sponsor":"Centre Hospitalier Annecy Genevois","startDate":"2020-02-05","conditions":["Infectious Disease","Endocarditis"],"enrollment":192,"completionDate":"2022-03-31"},{"nctId":"NCT00941356","phase":"PHASE2","title":"Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients","status":"WITHDRAWN","sponsor":"Bio-K Plus International Inc.","startDate":"2010-01","conditions":["MRSA Colonization"],"enrollment":0,"completionDate":"2016-07"},{"nctId":"NCT05329168","phase":"PHASE2","title":"ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis","status":"WITHDRAWN","sponsor":"Lysovant","startDate":"2022-05-01","conditions":["Bacteremia Due to Staphylococcus Aureus","Left Sided Infective Endocarditis (Disorder)","Right Sided Infective Endocarditis (Disorder)","Endocarditis Infective"],"enrollment":0,"completionDate":"2023-11-01"},{"nctId":"NCT03643952","phase":"PHASE2","title":"Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-06","conditions":["Bacteremia","Soft Tissue Infections","Skin Diseases, Infectious"],"enrollment":18,"completionDate":"2020-04-07"},{"nctId":"NCT03959345","phase":"PHASE4","title":"Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia","status":"TERMINATED","sponsor":"Miquel Pujol","startDate":"2019-05-31","conditions":["Methicillin Susceptible Staphylococcus Aureus Septicemia"],"enrollment":215,"completionDate":"2022-02-24"},{"nctId":"NCT02901717","phase":"PHASE3","title":"Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI","status":"UNKNOWN","sponsor":"Leonard-Meron Biosciences, Inc.","startDate":"2018-02-13","conditions":["Catheter-related Infections"],"enrollment":144,"completionDate":"2023-03"},{"nctId":"NCT04503252","phase":"","title":"Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-01-14","conditions":["Staphylococcus Aureus Infection"],"enrollment":50,"completionDate":"2022-03-28"},{"nctId":"NCT04320628","phase":"NA","title":"Randomized Double-Blind Controlled Clinical Trial","status":"COMPLETED","sponsor":"SerenaGroup, Inc.","startDate":"2020-05-20","conditions":["Chronic Wounds","Acute Wounds"],"enrollment":25,"completionDate":"2022-03-01"},{"nctId":"NCT01481935","phase":"NA","title":"Enhanced Room Cleaning in Intensive Care Units to Reduce Gown and Glove Contamination With Multi-drug-resistant Bacteria","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-08","conditions":["Infection Control"],"enrollment":190,"completionDate":"2012-05"},{"nctId":"NCT02684422","phase":"","title":"Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-07","conditions":["Methicillin-Resistant Staphylococcus Aureus","Cystic Fibrosis"],"enrollment":48,"completionDate":"2021-12"},{"nctId":"NCT02135302","phase":"PHASE1","title":"A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects","status":"COMPLETED","sponsor":"Tetraphase Pharmaceuticals, Inc","startDate":"2013-10","conditions":["Impaired Hepatic Function"],"enrollment":24,"completionDate":"2014-03"},{"nctId":"NCT01255943","phase":"","title":"Testing Spread and Implementation of Novel Methicillin Resistant Staphylococcal Aureus (MRSA)-Reducing Practices","status":"COMPLETED","sponsor":"MaineHealth","startDate":"2010-07","conditions":["Blood Stream Infections","MRSA Infections"],"enrollment":175,"completionDate":"2012-04"},{"nctId":"NCT03446053","phase":"PHASE1","title":"A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Intron Biotechnology, Inc.","startDate":"2018-02-07","conditions":["Healthy Volunteers","Anti-Bacterial Agents","Methicillin-Resistant Staphylococcus Aureus","Methicillin-Sensitive Staphylococcus Aureus Infection"],"enrollment":33,"completionDate":"2019-02-07"},{"nctId":"NCT03089697","phase":"PHASE2","title":"Phase IIa Clinical Study of N-Rephasin® SAL200","status":"TERMINATED","sponsor":"Intron Biotechnology, Inc.","startDate":"2017-03-07","conditions":["Staphylococcus Aureus Bacteremia","Anti-Bacterial Agents"],"enrollment":25,"completionDate":"2019-11-07"},{"nctId":"NCT01028105","phase":"NA","title":"Incidence and Relationship of Positive Preoperative Methicillin Resistant Staphylococcus Aureus (MRSA) Screens and Post-operative Infections","status":"TERMINATED","sponsor":"Inova Health Care Services","startDate":"2008-02","conditions":["Methicillin-resistant Staphylococcus Aureus Infection"],"enrollment":975,"completionDate":"2013-10"},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT00638157","phase":"PHASE4","title":"Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2009-02-13","conditions":["Infective Endocarditis"],"enrollment":24,"completionDate":"2011-11-09"},{"nctId":"NCT04176328","phase":"PHASE1","title":"Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Neupharma Srl","startDate":"2019-10-25","conditions":["Cystic Fibrosis"],"enrollment":12,"completionDate":"2020-09-30"},{"nctId":"NCT02842710","phase":"NA","title":"Staphylococcus Aureus Resistant to Methicillin (MRSA) Screening in Trauma","status":"WITHDRAWN","sponsor":"University Hospital, Toulouse","startDate":"2016-06-04","conditions":["Emergencies"],"enrollment":0,"completionDate":"2018-12-15"},{"nctId":"NCT04431440","phase":"","title":"Silver Nanoparticles in Multidrug Resistant Bacteria","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-06-01","conditions":["Multidrug Resistent Bacteria"],"enrollment":150,"completionDate":"2020-10-13"},{"nctId":"NCT02972983","phase":"PHASE4","title":"Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2016-12-01","conditions":["Methicillin Susceptible Staphylococcus Aureus Septicemia","Bacteremia"],"enrollment":102,"completionDate":"2019-09"},{"nctId":"NCT02790996","phase":"PHASE2","title":"Neonatal Vancomycin Trial","status":"TERMINATED","sponsor":"PENTA Foundation","startDate":"2017-02-27","conditions":["Late Onset Neonatal Sepsis"],"enrollment":242,"completionDate":"2020-04-01"},{"nctId":"NCT04409769","phase":"","title":"Evaluation of the Tolerance of Ceftaroline and Ceftobiprole in the Management of BJI / PJI","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2020-02-01","conditions":["Bone and Joint Infection","Antibiotic Reaction"],"enrollment":22,"completionDate":"2020-05-05"},{"nctId":"NCT03941951","phase":"NA","title":"Study to Optimize the Use of New Antibiotics","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2019-07-09","conditions":["Bacterial Infections","Fungal Infection"],"enrollment":900,"completionDate":"2022-12-31"},{"nctId":"NCT03132246","phase":"","title":"MICRO Study: Detecting Bacterial Infections Related to Orthopaedic Surgical Implants","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2014-04","conditions":["Open Reduction and Internal Fixation of Extremity Fractures"],"enrollment":260,"completionDate":"2018-07-31"},{"nctId":"NCT01138462","phase":"NA","title":"Control of MRSA in Nursing Homes: Decolonization vs Standard Precautions","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2010-06","conditions":["Methicillin-Resistant Staphylococcus Aureus"],"enrollment":157,"completionDate":"2011-12"},{"nctId":"NCT04310722","phase":"","title":"Gram-negative Bacilli and MRSA Screening in ICU in China","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2019-08-06","conditions":["Infections, Bacterial"],"enrollment":200,"completionDate":"2020-12"},{"nctId":"NCT03304873","phase":"PHASE3","title":"Retapamulin as a Decolonizing Agent for MRSA","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-12-01","conditions":["MRSA"],"enrollment":47,"completionDate":"2019-03-18"},{"nctId":"NCT04247854","phase":"NA","title":"Probiotics Pilot Project","status":"UNKNOWN","sponsor":"Rothman Institute Orthopaedics","startDate":"2020-02-12","conditions":["Staphylococcus Aureus"],"enrollment":20,"completionDate":"2021-01-22"},{"nctId":"NCT01438515","phase":"NA","title":"Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization","status":"COMPLETED","sponsor":"Horizon Health Network","startDate":"2008-08","conditions":["Methicillin-resistant Staphylococcus Aureus"],"enrollment":100,"completionDate":"2019-12-31"},{"nctId":"NCT03192124","phase":"","title":"Evaluating Bactisure Wound Lavage in Orthopedic Wounds","status":"COMPLETED","sponsor":"Zimmer Biomet","startDate":"2017-07-01","conditions":["Infection of Total Knee Joint Prosthesis"],"enrollment":40,"completionDate":"2019-03-22"},{"nctId":"NCT01746095","phase":"PHASE2","title":"Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Savara Inc.","startDate":"2013-03","conditions":["Cystic Fibrosis"],"enrollment":87,"completionDate":"2014-11"},{"nctId":"NCT02426918","phase":"PHASE2","title":"Study of Debio 1450 for Bacterial Skin Infections","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2015-05","conditions":["Bacterial Infections"],"enrollment":330,"completionDate":"2016-09"},{"nctId":"NCT04141787","phase":"PHASE4","title":"Ceftriaxone as Home IV for Staph Infections","status":"UNKNOWN","sponsor":"Vancouver Island Health Authority","startDate":"2019-07-11","conditions":["Staphylococcal Infections","Osteomyelitis","CNS Infection","Septic Arthritis","Diabetic Foot Infection","Vertebral Osteomyelitis","Abscess","Coagulase Negative Staphylococcal Infection"],"enrollment":310,"completionDate":"2024-03-30"},{"nctId":"NCT02223455","phase":"NA","title":"Building an Optimal Hand Hygiene Bundle","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-10-01","conditions":["Hand Hygiene","Health Care Associated Infection","Compliance"],"enrollment":58,"completionDate":"2019-03-01"},{"nctId":"NCT02991131","phase":"","title":"Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-12-17","conditions":["Skin Disease, Infectious"],"enrollment":108,"completionDate":"2018-11-21"},{"nctId":"NCT04097613","phase":"EARLY_PHASE1","title":"Betadine Rinses for Chronic Rhinosinusitis Prospective Cohort Study","status":"COMPLETED","sponsor":"St. Paul's Hospital, Canada","startDate":"2017-07-28","conditions":["Chronic Rhinosinusitis (Diagnosis)"],"enrollment":29,"completionDate":"2019-08-31"},{"nctId":"NCT02743585","phase":"NA","title":"Impact of Rapid Pathogen Identification From Blood Cultures (RABbIT)","status":"UNKNOWN","sponsor":"Tan Tock Seng Hospital","startDate":"2017-03-20","conditions":["Bacteremia","Sepsis","Fungemia","Blood Stream Infection"],"enrollment":832,"completionDate":"2020-07-02"},{"nctId":"NCT00966446","phase":"NA","title":"Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-09","conditions":["MRSA - Methicillin Resistant Staphylococcus Aureus Infection"],"enrollment":223,"completionDate":"2014-12"},{"nctId":"NCT01925066","phase":"PHASE2","title":"Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2013-08","conditions":["Pneumonia, Staphylococcal","Methicillin-Resistant Staphylococcus Aureus"],"enrollment":20,"completionDate":"2017-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000179727","MMSL":"1694","NDDF":"002689","UNII":"Q91FH1328A","VUID":"4018148","CHEBI":"CHEBI:6827","VANDF":"4018148","INN_ID":"1103","RXNORM":"2181306","UMLSCUI":"C0025643","chemblId":"CHEMBL575","ChEMBL_ID":"CHEMBL575","KEGG_DRUG":"D02196","DRUGBANK_ID":"DB01603","PDB_CHEM_ID":" MII","PUBCHEM_CID":"6087","SNOMEDCT_US":"373515001","IUPHAR_LIGAND_ID":"12264","SECONDARY_CAS_RN":"7246-14-2","MESH_DESCRIPTOR_UI":"D008712"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Apothecon","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.64 hours","clearance":"6.6 mL/min/kg","bioavailability":"0%","fractionUnbound":"0.43%","volumeOfDistribution":"0.32 L/kg"},"publicationCount":1718,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01CF03","allCodes":["J01CF03"]},"biosimilarFilings":[],"originalDeveloper":"Apothecon","recentPublications":[{"date":"2026","pmid":"41821921","title":"A Retrospective, Descriptive Analysis of MRSA Infections in a Low-Endemicity Region, Focusing on Empiric Treatment Adequacy.","journal":"Infection and drug resistance"},{"date":"2026 Mar 4","pmid":"41798992","title":"Mobile phone contamination among hospital staff: Focus on MRSA and ESBL-producing bacteria.","journal":"Journal of infection prevention"},{"date":"2026 Feb 27","pmid":"41757426","title":"Evaluation of the Antimicrobial Activity of a 3% Chlorhexidine/Ophytrium Mousse and Shampoo in 18 Healthy Dogs.","journal":"Veterinary dermatology"},{"date":"2026 Feb","pmid":"41653018","title":"Surgical methods for reducing early wound dehiscence after reconstruction surgery for pressure ulcer.","journal":"Journal of wound care"},{"date":"2026","pmid":"41626231","title":"Case Report: Fulminant shock due to PVL-positive Staphylococcus aureus in an adolescent-superantigen-negative sepsis with toxic shock-like features.","journal":"Frontiers in medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small Molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"APOTHECON","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"APOTHECON","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":"APOTHECON","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":null,"mah":"APOTHECON","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":"APOTHECON","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":"APOTHECON","brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:12:36.127012+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}